Mawson Adopts Poison Pill to Thwart Endeavor’s Hostile Takeover Bid

Event summary

  • Mawson’s board adopted a limited-duration stockholder rights agreement (poison pill) on February 2, 2026, to counter Endeavor’s rapid stock accumulation and takeover attempt.
  • Endeavor, led by Joshua Kilgore and Cody Smith, acquired 29.7% of Mawson’s shares by January 28, 2026, despite initially claiming no takeover plans in SEC filings.
  • The rights agreement triggers if any entity acquires 20% or more of Mawson’s stock without board approval, expiring on February 1, 2027.
  • Endeavor proposed a tender offer and Series A Preferred Equity Financing on January 8, 2026, which was rejected by Mawson’s board.
  • Mawson operates 129 megawatts of digital infrastructure capacity, focusing on carbon-free energy solutions for AI, HPC, and Bitcoin mining.

The big picture

Mawson’s adoption of a poison pill reflects a broader trend of companies defending against activist investors and hostile takeovers, particularly in high-growth sectors like digital infrastructure and Bitcoin mining. The move underscores the strategic importance of maintaining control over long-term value creation in an industry characterized by rapid technological change and high capital requirements. Endeavor’s aggressive tactics highlight the increasing role of activist investors in shaping corporate governance and operational strategies.

What we're watching

Governance Dynamics
Whether Mawson’s board can maintain control amid Endeavor’s aggressive stock accumulation and proxy fight.
Execution Risk
The pace at which Endeavor can escalate its campaign, including potential proxy battles or legal challenges.
Strategic Realignment
How Mawson’s focus on carbon-free energy and digital infrastructure will factor into Endeavor’s proposed leadership and strategy changes.